Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umifenovir effectiveness in hospitalized adults with COVID-19
IRCT20200322046833N1Phase 3Completed
- Sponsor
- Center for Progress and Development of Iran
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of umifenovir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Center for Progress and Development of Iran. Primary endpoint: Clinical improvement. Started Mar 2020; status: completed.
02
Drugs
umifenovir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200322046833N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200322046833N1.